Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Syndax Pharmaceuticals announced its R&D Day unveiling new pipeline assets, including SNDX-4321, a novel EGFR inhibitor targeting unmet needs in NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. The company highlighted progress on late-stage programs Revuforj and Niktimvo, with near-term clinical milestones expected throug…